Showing 81 - 90 of 36,303
Objectives: This prospective pharmacoeconomic study analyses and discusses the cost effectiveness (expressed as cost per life-year gained) of desirudin in comparison with a low molecular weight heparin (LMWH), enoxaparin, as prophylaxis against deep vein thrombosis (DVT) in total hip...
Persistent link: https://www.econbiz.de/10005404942
Objective: To examine the potential economic impact of treatment of Alzheimer's disease. Design: Regression-based simulation estimation of the long term costs of Alzheimer's disease under a number of treatment scenarios. Data from an epidemiological study conducted in Rotterdam, The Netherlands,...
Persistent link: https://www.econbiz.de/10005404953
Background: A number of new antiepileptic agents have been introduced within a short period of time. Direct comparisons are not available, and information about the balance between costs and effects for these new therapies is lacking. Objective: To introduce a first approximation of the cost...
Persistent link: https://www.econbiz.de/10005404957
Background: Clinical studies have demonstrated that esomeprazole is superior to omeprazole for the acute treatment of reflux oesophagitis. Objective: To compare the cost effectiveness of esomeprazole 40mg once daily with omeprazole 20mg once daily in patients with reflux oesophagitis. Methods:...
Persistent link: https://www.econbiz.de/10005404965
Background: The Fracture Intervention Trial (FIT) demonstrated that the bisphosphonate alendronate reduces the risk of hip, spine and wrist fracture in osteoporotic women by approximately one half. Objective: To use data from FIT to conduct a cost-effectiveness analysis of alendronate. Design: A...
Persistent link: https://www.econbiz.de/10005404966
The available literature on cost benefit, cost effectiveness and cost utility of different drug and non-drug regimens in preventing hip fractures was reviewed. The cost of a hip fracture and of the different treatment regimens varied considerably from one country to another. In primary...
Persistent link: https://www.econbiz.de/10005404992
For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far,...
Persistent link: https://www.econbiz.de/10005405003
Background: To meet the challenge of an aging population, providers and payors must optimize chronic wound care outcomes and contain costs. Objective: To explore the costs, outcomes, and effects of outcomes on costs of pressure and venous ulcer woundcare protocols. Design: Modeling study using...
Persistent link: https://www.econbiz.de/10005590178
Objective: The objective of this study was to assess the cost effectiveness of using epoetin-alpha (erythropoietin) to augment preoperative autologous donation (PAD) of blood prior to elective cardiac surgery. Design and setting: We designed a decision-analytic model incorporating the risk of...
Persistent link: https://www.econbiz.de/10005590267
Cost estimates from developed countries indicate that asthma accounts for up to 2% of the economic cost of all diseases. A large proportion of asthma-related costs are attributable to poor asthma control. Treatment strategies which improve clinical outcomes in patients with asthma, therefore,...
Persistent link: https://www.econbiz.de/10005590268